|
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial. |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi |
Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi |
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Eisai; Ipsen; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Mercedes Martínez Villacampa |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Esteve; Ipsen; SERVIER |
Speakers' Bureau - Amgen; Bristol-Myers Squibb |
Research Funding - Merck Serono |
|
|
Consulting or Advisory Role - Merck Serono; SERVIER |
Travel, Accommodations, Expenses - Amgen; Merck |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Merck; Roche; Sanofi; SERVIER; Sirtex Medical |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boston Scientific; Lilly O.; Medtronic; Pierre Fabre; Sanofi; SERVIER; Syrtex Pharma; Viatris |
Travel, Accommodations, Expenses - SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline |
Speakers' Bureau - MSD Oncology; Pierre Fabre |